MX2022015437A - Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas. - Google Patents

Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.

Info

Publication number
MX2022015437A
MX2022015437A MX2022015437A MX2022015437A MX2022015437A MX 2022015437 A MX2022015437 A MX 2022015437A MX 2022015437 A MX2022015437 A MX 2022015437A MX 2022015437 A MX2022015437 A MX 2022015437A MX 2022015437 A MX2022015437 A MX 2022015437A
Authority
MX
Mexico
Prior art keywords
myeloproliferative
telomerase inhibitors
treatment
myeloproliferative disorders
disorders
Prior art date
Application number
MX2022015437A
Other languages
English (en)
Inventor
Monic J Stuart
Stephen Kelsey
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of MX2022015437A publication Critical patent/MX2022015437A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se proporcionan métodos para reducir la proliferación de células progenitoras neoplásicas y aliviar los síntomas asociados en individuos diagnosticados con MPN o MDS o que se cree que tienen trastornos mieloproliferativos, tal como la trombocitopenia esencial (ET). En la presente también se proporcionan métodos para usar inhibidores de la telomerasa para mantener los conteos de plaquetas en la sangre en intervalos relativamente normales en la sangre de individuos diagnosticados o que se sospecha que tienen trastornos mieloproliferativos, tales como ET.
MX2022015437A 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas. MX2022015437A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
MX2022015437A true MX2022015437A (es) 2023-01-11

Family

ID=50883867

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015007169A MX372753B (es) 2012-12-07 2013-11-15 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
MX2020003276A MX2020003276A (es) 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
MX2022015437A MX2022015437A (es) 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2015007169A MX372753B (es) 2012-12-07 2013-11-15 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
MX2020003276A MX2020003276A (es) 2012-12-07 2015-06-05 Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.

Country Status (37)

Country Link
EP (3) EP3646876B1 (es)
JP (6) JP6433911B2 (es)
KR (4) KR20250114449A (es)
CN (2) CN111617252A (es)
AP (1) AP2015008504A0 (es)
AU (4) AU2013356533B2 (es)
BR (1) BR112015013260A2 (es)
CA (2) CA3188494A1 (es)
CL (2) CL2015001530A1 (es)
CY (2) CY1122169T1 (es)
DK (3) DK3646876T3 (es)
EA (1) EA032973B1 (es)
ES (3) ES2744790T3 (es)
FI (2) FI3646876T3 (es)
FR (1) FR25C1016I1 (es)
HK (1) HK1210940A1 (es)
HR (3) HRP20191784T1 (es)
HU (4) HUE049858T2 (es)
IL (3) IL280144B2 (es)
LT (4) LT2928477T (es)
MA (2) MA38193B1 (es)
ME (1) ME03538B (es)
MX (3) MX372753B (es)
MY (2) MY200076A (es)
NL (1) NL301326I2 (es)
NZ (1) NZ708920A (es)
PH (2) PH12019501008A1 (es)
PL (3) PL2928477T3 (es)
PT (3) PT2928477T (es)
RS (2) RS59363B1 (es)
SG (3) SG10202103341SA (es)
SI (3) SI3456333T1 (es)
SM (2) SMT201900567T1 (es)
TN (1) TN2015000249A1 (es)
UA (3) UA117116C2 (es)
WO (1) WO2014088785A1 (es)
ZA (3) ZA201504124B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014387A1 (en) 2004-07-02 2006-02-09 Geron Corporation Synthesis of protected 3’-amino nucleoside monomers
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
PE20160223A1 (es) 2013-08-07 2016-04-27 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
CA2929809C (en) 2013-11-06 2022-05-17 Ayalew Tefferi Methods and materials for treating hematological malignancies
KR102401252B1 (ko) * 2015-04-23 2022-05-24 제론 코포레이션 다가 양이온 염 조성물을 사용한 폴리뉴클레오티드 제조의 방법
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3658156A1 (en) * 2017-07-28 2020-06-03 Geron Corporation Methods of treating myelodysplastic syndrome
IL308399B2 (en) * 2018-04-30 2025-08-01 Kartos Therapeutics Inc Methods of treating cancer
JP2021525795A (ja) * 2018-05-25 2021-09-27 カルトス セラピューティクス，インコーポレイテッド 骨髄増殖性腫瘍を治療する方法
TW202539748A (zh) * 2018-07-31 2025-10-16 美商傑龍公司 辨識有可能受益於以端粒酶抑制劑治療之患者的方法
BR112021010406A2 (pt) 2018-11-29 2021-08-24 Geron Corporation Métodos de tratamento de síndrome mielodisplástica
CA3156376A1 (en) 2019-11-04 2021-05-14 Fei Huang Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
MX2023000760A (es) * 2020-07-17 2023-02-13 Geron Corp Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso.
WO2022159760A1 (en) * 2021-01-22 2022-07-28 The Regents Of The University Of California Methods for treating and ameliorating cancer
WO2024259369A1 (en) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
JP2001507229A (ja) 1996-12-20 2001-06-05 ジェロン コーポレイション テロメラーゼのｒｎａ成分を検出および阻害するための方法
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
WO2004070008A2 (en) * 2003-01-31 2004-08-19 Au Jessie L-S Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
EP3342425B1 (en) 2003-09-09 2019-12-18 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
WO2006014387A1 (en) 2004-07-02 2006-02-09 Geron Corporation Synthesis of protected 3’-amino nucleoside monomers
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PL2101789T3 (pl) 2006-10-30 2015-05-29 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
TN2015000249A1 (en) 2016-10-03
JP2022179684A (ja) 2022-12-02
ZA201504124B (en) 2017-05-31
LT2928477T (lt) 2019-10-10
CY1122169T1 (el) 2020-11-25
JP2018035196A (ja) 2018-03-08
KR20230028590A (ko) 2023-02-28
KR20250114449A (ko) 2025-07-29
DK3456333T3 (da) 2020-05-18
WO2014088785A8 (en) 2015-07-16
FR25C1016I1 (fr) 2025-06-20
ES2744790T3 (es) 2020-02-26
CN104936602A (zh) 2015-09-23
LT3456333T (lt) 2020-06-25
CN104936602B (zh) 2020-07-17
HRP20240624T1 (hr) 2024-08-02
PH12015501282B1 (en) 2015-08-24
KR20210107906A (ko) 2021-09-01
HUS2500019I1 (hu) 2025-05-28
PL3646876T3 (pl) 2024-07-22
NL301326I2 (nl) 2025-07-31
JP2016504307A (ja) 2016-02-12
AU2024203138A1 (en) 2024-07-25
FIC20250019I1 (fi) 2025-05-07
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
UA128370C2 (uk) 2024-06-26
ES2982897T3 (es) 2024-10-18
ZA202108991B (en) 2023-05-31
RS59363B1 (sr) 2019-11-29
IL280144A (en) 2021-03-01
HRP20191784T1 (hr) 2019-12-27
AU2013356533B2 (en) 2018-09-27
SI3456333T1 (sl) 2020-10-30
MA45504B1 (fr) 2021-10-29
NZ708920A (en) 2020-08-28
KR20150091130A (ko) 2015-08-07
JP6998191B2 (ja) 2022-02-04
AP2015008504A0 (en) 2015-06-30
MA38193A1 (fr) 2017-12-29
IL239266A0 (en) 2015-07-30
FI3646876T3 (fi) 2024-05-14
JP2025109842A (ja) 2025-07-25
SG10201802926XA (en) 2018-05-30
JP2020041001A (ja) 2020-03-19
MA45504A1 (fr) 2020-05-29
AU2020267142B2 (en) 2024-05-16
PT2928477T (pt) 2019-10-25
JP2022050537A (ja) 2022-03-30
UA117116C2 (uk) 2018-06-25
SMT202000328T1 (it) 2020-07-08
EP3646876B1 (en) 2024-02-14
CA2892907C (en) 2023-03-21
HK1210940A1 (zh) 2016-05-13
EA201590878A1 (ru) 2016-04-29
ZA202212327B (en) 2025-03-26
WO2014088785A1 (en) 2014-06-12
CL2017002156A1 (es) 2018-05-04
IL239266B (en) 2019-11-28
EP2928477A1 (en) 2015-10-14
KR102294819B1 (ko) 2021-09-01
MX2015007169A (es) 2016-03-31
LT3646876T (lt) 2024-05-10
MY180634A (en) 2020-12-03
EP2928477A4 (en) 2016-09-21
HUE049858T2 (hu) 2020-11-30
DK2928477T3 (da) 2019-10-07
EP3646876A1 (en) 2020-05-06
PT3646876T (pt) 2024-05-15
EP2928477B1 (en) 2019-07-24
HUE066402T2 (hu) 2024-07-28
ME03538B (me) 2020-07-20
UA126015C2 (uk) 2022-08-03
MY200076A (en) 2023-12-06
AU2018282364A1 (en) 2019-05-23
SG10202103341SA (en) 2021-05-28
RS60401B1 (sr) 2020-07-31
PT3456333T (pt) 2020-06-01
IL317233A (en) 2025-01-01
JP7288098B2 (ja) 2023-06-06
EP3456333B8 (en) 2020-05-13
BR112015013260A2 (pt) 2018-02-06
DK3646876T3 (da) 2024-05-06
NZ748134A (en) 2020-10-30
MA38193B1 (fr) 2018-12-31
CY1123206T1 (el) 2021-10-29
IL280144B1 (en) 2025-01-01
EP3456333B1 (en) 2020-04-01
PL2928477T3 (pl) 2020-03-31
LTPA2025517I1 (es) 2025-05-26
MX2020003276A (es) 2020-07-20
CA3188494A1 (en) 2014-06-12
CL2015001530A1 (es) 2016-03-28
CN111617252A (zh) 2020-09-04
AU2020267142A1 (en) 2020-12-03
KR102662590B1 (ko) 2024-05-03
IL280144B2 (en) 2025-05-01
AU2020267142C1 (en) 2024-08-08
ES2789176T3 (es) 2020-10-26
SMT201900567T1 (it) 2019-11-13
PH12019501008A1 (en) 2022-11-14
PL3456333T3 (pl) 2020-09-21
EA032973B1 (ru) 2019-08-30
AU2013356533A1 (en) 2014-06-12
SI3646876T1 (sl) 2024-07-31
CA2892907A1 (en) 2014-06-12
HK1212226A1 (en) 2016-06-10
SI2928477T1 (sl) 2019-11-29
MX372753B (es) 2020-06-26
EP3456333A1 (en) 2019-03-20
JP6433911B2 (ja) 2018-12-05
SG11201504383TA (en) 2015-07-30
PH12015501282A1 (en) 2015-08-24

Similar Documents

Publication Publication Date Title
ZA202212327B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
MY185016A (en) Progenitor cells of mesodermal lineage
SG178991A1 (en) Anti-gitr antibodies
WO2014144847A3 (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
IN2015DN03862A (es)
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2019007890A (es) Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
IN2014DN09228A (es)
NZ628433A (en) Chitosan-derived compositions
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
WO2012135818A3 (en) Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis
AU2013208087A8 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
EA201990799A1 (ru) Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм
WO2015060736A3 (en) The use of egfr and hgfr agonists as anticancer drugs acting on tumour cells of certain phenotype
MA54889A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
UA112059C2 (uk) Комбінована терапія із кріохірургією і іміквімодом для лікування актинічного кератозу (варіанти)
EA201792475A1 (ru) Клетки-предшественники мезодермальной линии
AU339611S (en) Multifunctional seating
AU341802S (en) Shelving